Any current/future new fundraising through debt or equity?

The document does not explicitly mention any current or future plans for fundraising through debt or equity. The company is focusing on organic and inorganic growth opportunities with added resources post-merger. There is no direct reference to issuing new shares or taking on additional debt. Discussions reveal capital expenditure plans primarily for capacity expansion (e.g., multi-synthesis plant in Dahej with a CAPEX of around Rs 30 crores), which is expected to be funded internally. Monetisation of real estate assets is ongoing, possibly aimed at raising funds, but specific fundraising plan

Any current/future capex/capital investment/strategic investment?

Construction of a multi-synthesis plant in Dahej with a total CAPEX of around Rs 30 crores is underway. No other major CAPEX is expected in the current financial year. Pharma division capacity is expected to increase by 25% by Q1 FY22 due to the completion of the Rs 30 crore CAPEX. The Saykha project involves a planned investment of over Rs 200 crores over the next few years, to be done in a phased manner. Saykha project will focus on manufacturing minerals, chemical multi synthesis capabilities, and valorizing by-products like wool grease and fish oil to cholesterol. Commercial prod

Future growth expectations in sales/revenue/volumes?

The company expects a top-line growth at a CAGR of 15% over the next 5 years. Capacity utilization is currently around 80% and is expected to increase with new expansions. A multi-synthesis plant under construction will add ~25% capacity by Q1 FY22. The pharma division expects a 25% capacity increase by Q1 FY22 from ongoing CAPEX of around Rs. 30 crores. Demand for Vitamin D3 in the human segment is rising, both domestically and in exports; animal feed demand remains subdued due to factors like COVID impact on meat industry. New product launches including minerals and premix variants

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects top-line growth at a CAGR of 15% over the next 5 years. Bulk drug division anticipates achieving an average EBITDA margin of around 25% in the long run despite price volatility. Capacity expansion ongoing: Multi-synthesis plant at Dahej to increase capacity by ~25% by Q1 FY22. The pharma division is close to full capacity utilization, with expected 25% capacity increase by FY22 due to Rs 30 crore CAPEX. The company aims to sustain and improve EBITDA margins through backward integration and volume growth despite feed-grade price pressures. Real estate monetization

Current/ Expected Orderbook/ Pending Orders?

The document does not provide explicit details on the current or expected order book or pending orders for the company. However, it mentions capacity utilization is close to 80% and above, indicating ongoing demand. The pharma division is near full capacity utilization, with a planned 25% capacity increase by Q1 FY22. Bulk drug division is dealing with market volatility, making steady-state predictions difficult. No specific information on pending orders or size of orderbook is stated. The company acknowledges increased demand for Vitamin D3 on human side but subdued demand on animal feed side

Fermenta Biotec.Q2 FY21Pharmaceuticals & Biotechnology

Fermenta Biotec. Q2 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹417.55P/E: 22.4Market Cap: ₹1.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects a top-line growth at a CAGR of 15% over the next 5 years.
Capacity utilization is currently around 80% and is expected to increase with new expansions.
A multi-synthesis plant under construction will add ~25% capacity by Q1 FY22.
The pharma division expects a 25% capacity increase by Q1 FY22 from ongoing CAPEX of around Rs. 30 crores.
Demand for Vitamin D3 in the human segment is rising, both domestically and in exports; animal feed demand remains subdued due to factors like COVID impact on meat industry.
New product launches including minerals and premix variants of D3 are planned, aligned with government fortification programs targeting edible oil and milk by FY22.
Strategic partnerships and geographic expansions (Europe, USA) are expected to support growth without significant additional CAPEX.

Margin guidance

Category 3

The company expects top-line growth at a CAGR of 15% over the next 5 years.
Bulk drug division anticipates achieving an average EBITDA margin of around 25% in the long run despite price volatility.
Capacity expansion ongoing: Multi-synthesis plant at Dahej to increase capacity by ~25% by Q1 FY22.
The pharma division is close to full capacity utilization, with expected 25% capacity increase by FY22 due to Rs 30 crore CAPEX.
The company aims to sustain and improve EBITDA margins through backward integration and volume growth despite feed-grade price pressures.
Real estate monetization is planned but delayed due to COVID-19 uncertainties.
The company is diversifying product offerings (e.g., milk and oil fortification) with expected launches by FY22, targeting new markets.
Overall, earnings and profitability are expected to improve gradually, supported by capacity expansions and product diversification.

See what Fermenta Biotec. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The document does not explicitly mention any current or future plans for fundraising through debt or equity.
The company is focusing on organic and inorganic growth opportunities with added resources post-merger.
There is no direct reference to issuing new shares or taking on additional debt.
Discussions reveal capital expenditure plans primarily for capacity expansion (e.g., multi-synthesis plant in Dahej with a CAPEX of around Rs 30 crores), which is expected to be funded internally.
Monetisation of real estate assets is ongoing, possibly aimed at raising funds, but specific fundraising plans via equity or debt are not indicated.
No mention of a public or private fundraising round in the visible sections of the report.

Order book

The document does not provide explicit details on the current or expected order book or pending orders for the company.
However, it mentions capacity utilization is close to 80% and above, indicating ongoing demand.
The pharma division is near full capacity utilization, with a planned 25% capacity increase by Q1 FY22.
Bulk drug division is dealing with market volatility, making steady-state predictions difficult.
No specific information on pending orders or size of orderbook is stated.
The company acknowledges increased demand for Vitamin D3 on human side but subdued demand on animal feed side due to industry slowdown.
Supply chain improvements and logistic partnerships (e.g., in Germany) are mentioned, likely supporting order fulfillment.
Overall, detailed order book status is not explicitly disclosed in the provided pages.

See what Fermenta Biotec. management said on order book — free account, 30 seconds.

Capex plans

Yes

Construction of a multi-synthesis plant in Dahej with a total CAPEX of around Rs 30 crores is underway.
No other major CAPEX is expected in the current financial year.
Pharma division capacity is expected to increase by 25% by Q1 FY22 due to the completion of the Rs 30 crore CAPEX.
The Saykha project involves a planned investment of over Rs 200 crores over the next few years, to be done in a phased manner.
Saykha project will focus on manufacturing minerals, chemical multi synthesis capabilities, and valorizing by-products like wool grease and fish oil to cholesterol.
Commercial production at Saykha is expected to start by FY23 after environment clearance and construction.
The company is also undertaking R&D projects, doubling R&D space, and increasing employees to support future growth.

Track Fermenta Biotec. — get its next earnings analysis in your feed

How does Fermenta Biotec. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisFermenta Biotec.

Rev 3Mar 3

See where Fermenta Biotec. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Fermenta Biotec. rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotec. against every Pharmaceuticals & Biotechnology company (Q2 FY21) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Fermenta Biotec.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Fermenta Biotec. Q2 FY21 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Fermenta Biotec. rank in Pharmaceuticals & Biotechnology?

Continue your research

What Fermenta Biotec.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season